| ID | Sequence | Length | GC content |
|---|---|---|---|
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5147 nt | 0.4230 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5135 nt | 0.4232 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5150 nt | 0.4231 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5144 nt | 0.4228 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5132 nt | 0.4230 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5138 nt | 0.4233 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5147 nt | 0.4230 | |
| GCACUUGGGCGAGAGCUGGAACGUGGACCAGAGCUCGGAUCCCAUCGCA… | 5135 nt | 0.4232 |
This gene encodes a receptor tyrosine kinase. This gene was initially identified as a homolog of the feline sarcoma viral oncogene v-kit and is often referred to as proto-oncogene c-Kit . The canonical form of this glycosylated transmembrane protein has an N-terminal extracellular region with five immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain at the C-terminus. Upon activation by its cytokine ligand, stem cell factor (SCF), this protein phosphorylates multiple intracellular proteins that play a role in in the proliferation, differentiation, migration and apoptosis of many cell types and thereby plays an important role in hematopoiesis, stem cell maintenance, gametogenesis, melanogenesis, and in mast cell development, migration and function. This protein can be a membrane-bound or soluble protein. Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2020] CIViC Summary for KIT Gene c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.
A study in humans demonstrated that the KIT was upregulated during long-term weight loss in subcutaneous adipose tissue of weight losers [Bollepalli et al. DOI:10.1038/ijo.2017.245]. In a separate human study, single-cell transcriptome analysis identified the KIT as a specific marker for cavernosal trabecular endothelial cells, with its expression pattern differing between normal and pathological erectile dysfunction states [Zhao et al. DOI:10.1038/s41467-022-31950-9].